Pfizer markets Vyndamax as the "only once-daily capsule". The evidence says otherwise.
Patients are not informed that a cheaper rival pill exists, or that Pfizer paid the support group it recommends.
California's commercial health plans spent $14.9 billion on prescription drugs in 2024, and Medi-Cal spent $19.4 billion in fiscal 2024-25. Yet the promotion and funding behind those drugs remain hard for patients to see. Pfizer's Vyndamax shows how.
Start with the money. Pfizer's Vyndamax materials direct ATTR-CM patients to advocacy organizations, including Amyloidosis Support Groups. Pfizer's own records show $50,000 paid to Amyloidosis Support Groups, Inc. in 2016. Pfizer disclosed the payment, but in a corporate PDF that no newly diagnosed patient will find. The referral is prominent and the financial link is not.
Then the wording. Pfizer describes Vyndamax as the only once-daily capsule for ATTR-CM. Advocates object that the phrase leaves patients believing they have fewer options than they do. Word by word, it holds up: BridgeBio's Attruby, the rival oral stabilizer, is a twice-daily tablet. A patient hears "only" and does not hear that a cheaper pill exists.
The FDA has said promotion can be accurate and still misleading. In September 2025 it sent thousands of warning letters and about 100 cease-and-desist letters over deceptive advertising. That enforcement works claim by claim, after the fact. Nothing requires a manufacturer to say, at the point of referral, that it has funded the group it recommends. The US has its own false-advertising and consumer-protection laws, and should use them.
Sources
- ibtimes.com · ibtimes.com/californians-deserve-greater-drug-transparency-3807953
- cdn.pfizer.com · cdn.pfizer.com/pfizercom/responsibility/grants_contributions/Yes_Report-20170428.pdf
- fda.gov · fda.gov/news-events/press-announcements/fda-launches-crackdown-deceptive-drug-advertising
Cite this report
The Precedent. "Pfizer markets Vyndamax as the "only once-daily capsule". The evidence says otherwise.." October 10, 2026. https://theprecedent.org/article/pfizer-markets-vyndamax-as-the-only-once-daily-capsule-the-evidence-says-otherwi
